Selected article for: "cc NC International license and China study"
Author: Yanli Liu; Wenwu Sun; Jia Li; Liangkai Chen; Yujun Wang; Lijuan Zhang; Li Yu
Title: Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019
  • Document date: 2020_2_20
    • ID: mlkxcn5k_10
    Snippet: is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10. 1101 /2020 reaction, and coagulation dysfunction might evolve in the course of ARDS resulted 2 5 8 from SARS-CoV-2. with ARDS, which might in turn help to guide our medical therapy. The medical management of ARDS has advanced remarkably during the past decades to increased mortality in the front-line epidemic area during the early outbreak period. Th.....
    Document: is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10. 1101 /2020 reaction, and coagulation dysfunction might evolve in the course of ARDS resulted 2 5 8 from SARS-CoV-2. with ARDS, which might in turn help to guide our medical therapy. The medical management of ARDS has advanced remarkably during the past decades to increased mortality in the front-line epidemic area during the early outbreak period. The epidemic spread knows no borders. We are deeply concerned about the current future, a multi-center and follow-up study with a larger cohort is eagerly warranted. In the current study from one of the designated hospitals in Wuhan, China, the help to guide the risk stratification and therapeutic strategy for COVID-19 patients. . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • cc NC ND International license and coagulation dysfunction: 1
    • cc NC ND International license and current future: 1
    • cc NC ND International license and current study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • cc NC ND International license and epidemic area: 1
    • cc NC ND International license and epidemic spread: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • cc NC ND International license and follow multi center study: 1
    • cc NC ND International license and increase mortality: 1, 2, 3, 4
    • cc NC ND International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc NC ND International license and large cohort: 1, 2, 3
    • coagulation dysfunction and current study: 1, 2
    • coagulation dysfunction and epidemic area: 1
    • coagulation dysfunction and increase mortality: 1, 2, 3, 4, 5
    • coagulation dysfunction and International license: 1
    • current future and epidemic area: 1
    • current future and epidemic spread: 1, 2, 3
    • current future and increase mortality: 1, 2, 3, 4, 5
    • current future and International license: 1, 2
    • current future and large cohort: 1, 2, 3
    • current study and epidemic area: 1, 2, 3, 4